Expression of Surface Molecules on Multiple Myeloma Cells and their Potential Role in Pathogenesis, Prognosis, and Treatment

Kotwica, K.; Cioch, Maria; Dmoszyńska, Anna

doi:10.4172/2155-9929.1000103

Cited by 2 publications

(3 citation statements)

References 149 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MM is responsible for ∼1% of all cancers and ∼2% of cancer deaths . The development of MM involves a series of genetic alterations and changes in the BM microenvironment, favouring the growth of the tumour and the collapse of local immune control .…”

Section: Introductionmentioning

confidence: 99%

“…Despite recent advances in treatment, MM remains an incurable haematological malignancy. Accordingly, it is important to improved our knowledge of novel, as yet unidentified, molecules or pathways that improve our understanding of the development of malignant clones of plasma, which will faster the development of new therapies . MM cells and stromal cells interact via adhesion molecules and cytokine networks to simultaneously promote MM cell survival, drug resistance, angiogenesis and disturbed bone metabolism .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Upregulation of CD200 is associated with regulatory T cell expansion and disease progression in multiple myeloma

Aref

Azmy

El‐Gilany

2015

Hematological Oncology

View full text Add to dashboard Cite

Immune dysfunction is an important feature of multiple myeloma (MM) leading to infections, enhancement of tumour growth and resistance to chemotherapy. The overexpression of CD200, expansion of T regulatory (Treg) cell and increased levels of immune modulatory cytokines like IL10, IL6 and transforming growth factor beta (TGFβ) were suggested to have a role in this context. The aim of this study was to assess CD200 expression, Treg percentage by flow cytometry and immune modulatory cytokines (IL10, IL6, TGFβ) by enzyme-linked immunosorbent assay in MM patients at diagnosis. This study included 50 MM patients at diagnosis and 20 healthy controls. The positive CD200 expression was detected in 72% of MM patients. Among the CD200 positive group, 4/13 patients (30.8%) were classified as stage I, 18/23 (78.3%) were in stage II and 14/14 (100%) were in stage III; according to International scoring system. Treg percentage was significantly higher in stage III, followed by stage II then stage I (p < 0.01). Serum IL6, IL10 and TGFβ were significantly higher in MM patients as compared with controls (p < 0.01, p < 0.01, p < 0.05, respectively). The increased expression of CD200 and Treg percentages was associated with increased severity biomarkers (serum LDH and β2 microglobulin). The degree of CD200 expression was significantly positively correlated to Treg percentage (r = 0.565, p < 0.01). Analysis of the CD200 negative patients had a better progression free survival (p = 0.032) and overall survival (p = 0.04) as compared with those positive for CD200 expression. These findings illustrate a clear correlation between myeloma cell CD200 expression level and the frequency of immunosuppressive Treg cells. In conclusion, increased expression of CD200, expansion of suppressive Treg cells and elevation of cytokines might have a role in MM progression in this cohort of patients. Copyright © 2015 John Wiley & Sons, Ltd.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Upregulation of CD200 is associated with regulatory T cell expansion and disease progression in multiple myeloma

Aref

Azmy

El‐Gilany

2015

Hematological Oncology

View full text Add to dashboard Cite

show abstract

“…Multiple myeloma cells express a number of surface molecules capable of activating downstream anti-apoptotic signaling pathways which could favor their growth and survival. Such cell surface molecules have been considered to be prognostic factors for multiple myeloma (MM), may become possible therapeutic targets in the future [16].…”

Section: Genetic Instability As Prognostic Factorsmentioning

confidence: 99%

Biomarkers and their Role in Premonition, Interpretation and Treatment of Cancer

YRKM¹,

Dattatreya²,

SY³

et al. 2011

J Cancer Sci Ther

View full text Add to dashboard Cite

The Prognosis and Diagnosis of CANCER has become easier now days, in earlier days, there has been a degree of difficulty in the premonition and Interpretation of the disease, either of the carcinomas, sarcomas, lymphomas and/ or etc cancers types are very dreadful diseases which do not have methods of earlier detections. Biomarkers' are the astounding promise for both of the Diagnosis and Prognosis of the cancer. They set a future for the further eagle eye study of various cancers. In this review it will be stating various types of biomarkers whether they are immunological origin or of molecular origin. In the finale statement is we tried to summarize and hypothesize the types in the biomarkers' for the prognosis and diagnosis of Cancer.

show abstract

Expression of Surface Molecules on Multiple Myeloma Cells and their Potential Role in Pathogenesis, Prognosis, and Treatment

Cited by 2 publications

References 149 publications

Upregulation of CD200 is associated with regulatory T cell expansion and disease progression in multiple myeloma

Upregulation of CD200 is associated with regulatory T cell expansion and disease progression in multiple myeloma

Biomarkers and their Role in Premonition, Interpretation and Treatment of Cancer

Contact Info

Product

Resources

About